Shares of Hims & Hers Health surged significantly on Monday, reaching a 52-week high and rising by 23% in a single day, with a 48% increase over the past five days and a 63% rise in six days. The telehealth company also achieved a new all-time high and traded back to $30 during the session. It is seen as a potential beneficiary of former President Donald Trump's choice for FDA Commissioner, Dr. Marty Makary, who is speculated to be a strong advocate for telehealth services. Hunterbrook Media and other analysts have highlighted the company's growth potential under the new administration. Currently trading at approximately 38 times projected earnings for this year, with earnings growth exceeding 70% this year and expected to grow over 20% in the coming years, the stock has attracted significant investor interest. Analysts remain cautiously optimistic, with some projecting the stock could reach $40.